Epigenetics As a Therapeutic Target in Breast Cancer

Overview

Journal J Mammary Gland Biol Neoplasia

Date 2012 Jul 28

PMID 22836913

Citations 49

Authors

Roisin Connolly

Vered Stearns

Affiliations

Soon will be listed here.

Abstract

Epigenetics refers to alterations in gene expression due to modifications in histone acetylation and DNA methylation at the promoter regions of genes. Unlike genetic mutations, epigenetic alterations are not due to modifications in the gene primary nucleotide sequence. The importance of epigenetics in the initiation and progression of breast cancer has led many investigators to incorporate this novel and exciting field in breast cancer drug development. Several drugs that target epigenetic alterations, including inhibitors of histone deacetylase (HDAC) and DNA methyltransferase (DNMT), are currently approved for treatment of hematological malignancies and are available for clinical investigation in solid tumors. In this manuscript, we review the critical role of epigenetics in breast cancer including the potential for epigenetic alterations to serve as biomarkers determining breast cancer prognosis and response to therapy. We highlight initial promising results to date with use of epigenetic modifiers in patients with breast cancer and the ongoing challenges involved in the successful establishment of these agents for the treatment of breast cancer.

Citing Articles

CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis.

Ji D, Luo Y, Wang J, Chen S, Lan B, Ma F BMC Cancer. 2023; 23(1):805.

PMID: 37644396 PMC: 10463765. DOI: 10.1186/s12885-023-11290-7.

Combined low levels of H4K16ac and H4K20me3 predicts poor prognosis in breast cancer.

Wang B, Zhou M, Gan X, Ren Y, Yang Y, Weng Z Int J Clin Oncol. 2023; 28(9):1147-1157.

PMID: 37428307 DOI: 10.1007/s10147-023-02378-y.

Efficacy and exploratory biomarker analysis of entinostat plus exemestane in advanced or recurrent breast cancer: phase II randomized controlled trial.

Iwata H, Nakamura R, Masuda N, Yamashita T, Yamamoto Y, Kobayashi K Jpn J Clin Oncol. 2022; 53(1):4-15.

PMID: 36398439 PMC: 9825728. DOI: 10.1093/jjco/hyac166.

Epigenetic drugs induce the potency of classic chemotherapy, suppress post-treatment re-growth of breast cancer, but preserve the wound healing ability of stem cells.

Zheng A, Bilbao M, Sookram J, Linden K, Morgan A, Ostrovsky O Cancer Biol Ther. 2022; 23(1):254-264.

PMID: 35389825 PMC: 8993057. DOI: 10.1080/15384047.2022.2052540.

miRNome Profiling Reveals Shared Features in Breast Cancer Subtypes and Highlights miRNAs That Potentially Regulate MYB and EZH2 Expression.

Correa S, Lopes F, Panis C, Basili T, Binato R, Abdelhay E Front Oncol. 2021; 11:710919.

PMID: 34646766 PMC: 8502886. DOI: 10.3389/fonc.2021.710919.

References

Weiss A, Stambaugh J, Mastrangelo M, Laucius J, Bellet R . Phase I study of 5-azacytidine (NSC-102816) . Cancer Chemother Rep. 1972; 56(3):413-9. View

Scandura J, Roboz G, Moh M, Morawa E, Brenet F, Bose J . Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML. Blood. 2011; 118(6):1472-80. PMC: 3156041. DOI: 10.1182/blood-2010-11-320093. View

Chuang J, Warner S, Vollmer D, Vankayalapati H, Redkar S, Bearss D . S110, a 5-Aza-2'-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth. Mol Cancer Ther. 2010; 9(5):1443-50. PMC: 2868087. DOI: 10.1158/1535-7163.MCT-09-1048. View

Fenaux P, Mufti G, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A . Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009; 10(3):223-32. PMC: 4086808. DOI: 10.1016/S1470-2045(09)70003-8. View

Zhang Z, Yamashita H, Toyama T, Sugiura H, Omoto Y, Ando Y . HDAC6 expression is correlated with better survival in breast cancer. Clin Cancer Res. 2004; 10(20):6962-8. DOI: 10.1158/1078-0432.CCR-04-0455. View

Jones P, Baylin S . The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002; 3(6):415-28. DOI: 10.1038/nrg816. View

Keen J, Yan L, Mack K, Pettit C, Smith D, Sharma D . A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine. Breast Cancer Res Treat. 2003; 81(3):177-86. DOI: 10.1023/A:1026146524737. View

Sharma D, Saxena N, Davidson N, Vertino P . Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. Cancer Res. 2006; 66(12):6370-8. PMC: 2925469. DOI: 10.1158/0008-5472.CAN-06-0402. View

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

10.

Qin T, Youssef E, Jelinek J, Chen R, Yang A, Garcia-Manero G . Effect of cytarabine and decitabine in combination in human leukemic cell lines. Clin Cancer Res. 2007; 13(14):4225-32. DOI: 10.1158/1078-0432.CCR-06-2762. View

11.

Munster P, Thurn K, Thomas S, Raha P, Lacevic M, Miller A . A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer. 2011; 104(12):1828-35. PMC: 3111195. DOI: 10.1038/bjc.2011.156. View

12.

Luu T, Morgan R, Leong L, Lim D, McNamara M, Portnow J . A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. Clin Cancer Res. 2008; 14(21):7138-42. PMC: 3543872. DOI: 10.1158/1078-0432.CCR-08-0122. View

13.

Bali P, Pranpat M, Swaby R, Fiskus W, Yamaguchi H, Balasis M . Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2. Clin Cancer Res. 2005; 11(17):6382-9. DOI: 10.1158/1078-0432.CCR-05-0344. View

14.

Gray R, Bhattacharya S, Bowden C, Miller K, Comis R . Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol. 2009; 27(30):4966-72. PMC: 2799052. DOI: 10.1200/JCO.2008.21.6630. View

15.

Munster P, Troso-Sandoval T, Rosen N, Rifkind R, Marks P, Richon V . The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res. 2001; 61(23):8492-7. View

16.

Foulks J, Parnell K, Nix R, Chau S, Swierczek K, Saunders M . Epigenetic drug discovery: targeting DNA methyltransferases. J Biomol Screen. 2011; 17(1):2-17. DOI: 10.1177/1087057111421212. View

17.

Yang X, Phillips D, FERGUSON A, Nelson W, Herman J, Davidson N . Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res. 2001; 61(19):7025-9. View

18.

Ramaswamy B, Fiskus W, Cohen B, Pellegrino C, Hershman D, Chuang E . Phase I-II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo. Breast Cancer Res Treat. 2011; 132(3):1063-72. PMC: 3486521. DOI: 10.1007/s10549-011-1928-x. View

19.

Jenuwein T, Allis C . Translating the histone code. Science. 2001; 293(5532):1074-80. DOI: 10.1126/science.1063127. View

20.

Raffoux E, Cras A, Recher C, Boelle P, de Labarthe A, Turlure P . Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome. Oncotarget. 2011; 1(1):34-42. PMC: 4053545. DOI: 10.18632/oncotarget.106. View